Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer

Galeterone is a selective, multitargeted agent that inhibits CYP17, antagonizes the androgen receptor (AR), and reduces AR expression in prostate cancer cells by causing an increase in AR protein degradation. These open-label phase I and II studies [Androgen Receptor Modulation Optimized for Respons...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2016-03, Vol.22 (6), p.1356-1363
Hauptverfasser:	Montgomery, Bruce, Eisenberger, Mario A, Rettig, Matthew B, Chu, Franklin, Pili, Roberto, Stephenson, Joseph J, Vogelzang, Nicholas J, Koletsky, Alan J, Nordquist, Luke T, Edenfield, William J, Mamlouk, Khalid, Ferrante, Karen J, Taplin, Mary-Ellen
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Androstadienes - pharmacology Androstadienes - therapeutic use Antineoplastic Agents, Hormonal - pharmacology Antineoplastic Agents, Hormonal - therapeutic use Benzimidazoles - pharmacology Benzimidazoles - therapeutic use Combined Modality Therapy Humans Male Middle Aged Neoplasm Metastasis Neoplasm Staging Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - pathology Receptors, Androgen - metabolism Retreatment Signal Transduction - drug effects Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!